The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice
Abstract
Mutations in the tumor suppressor p53 are detectable in over 50% of all human malignancies. Mutant p53 protein is incapable of transactivating its downstream target genes that are required for DNA repair and apoptosis. Chronic exposure to UVB induces p53 mutations and is carcinogenic in both murine and human skin. CP-31398, a styrylquinazoline compound, restores the tumor suppressor functions of mutant forms of p53 in tumor cells. However, its effectiveness in vivo remains unclear. Here, we demonstrate that CP-31398 blocked UVB-induced skin carcinogenesis and was associated with increases in p53, p21, and BclXs. CP-31398 downregulated Bcl2, proliferating nuclear cell antigen, and cyclin D1. Activation of caspase-3 and cleavage of poly (ADP-ribose) polymerase also occurred in both tumor and perilesional skin following treatment. CP-31398 induced the expression of p53-dependent target proteins, and this was followed by apoptosis in UVB-irradiated wild-type mice but not in their p53-deficient littermates. Similar effects were observed in human skin carcinoma A431 cells expressing mutant p53. In addition, CP-31398 induced mitochondrial translocation of p53, leading to changes in mitochondrial membrane permeability pore transition (MPT) and consequent cytochrome c release in these cells. Blocking MPT diminished p53 translocation and apoptosis. These studies indicate that reconstituting p53 tumor suppressor functions in vivo by small molecular weight compounds may block the pathogenesis and progression of skin cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Specifically, the concentration and timing of drug administration significantly impact therapeutic responses.”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [337]
In the citing paper
“For example, CP31398 induced apoptosis in A431 cells expressing mutant p53 but not in normal human epidermal keratinocytes (NHEKs) expressing wild-type p53.337”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [337]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Di Lisa, F., Blank, P. S., Colonna, R., Gambassi, G., Silverman, H. S., Stern, M. D., & Hansford, R. G. (1995) · The Journal of Physiology · doi:10.1113/jphysiol.1995.sp020786 · Cited by 286
Zhao, Y., Chaiswing, L., Velez, J. M., Batinic-Haberle, I., Colburn, N. H., Oberley, T. D., & St. Clair, D. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3835 · Cited by 245
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Cell type and DNA damage specific response of human skin cells to environmental agents
D’Errico, M., Lemma, T., Calcagnile, A., Santis, L. P. D., & Dogliotti, E. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.06.009 · Cited by 98
Research works printed but not linked: 17
- van Kranen, 1999, J. Epidemiol., 9, S58, 10.2188/jea.9.6sup_58 · DOI
- Mitchell, 1989, Photochem. Photobiol., 49, 805, 10.1111/j.1751-1097.1989.tb05578.x · DOI · Paper page
- van Kranen, 2005, Mutat. Res., 571, 81, 10.1016/j.mrfmmm.2004.07.018 · DOI
- Roth, 2003, Methods Mol. Biol., 223, 577
- Wang, 2003, Cancer Biol. Ther., 2, S55
- Bickers, 2000, J. Dermatol., 27, 691, 10.1111/j.1346-8138.2000.tb02259.x · DOI
- Starcher, 1995, Ciba Found. Symp., 192, 338
- Takimoto, 2004, Gan To Kagaku Ryoho., 31, 1309
- Reiss, 1992, Oncol. Res., 4, 349
- Park, 1994, Oncogene., 9, 1899
- Ogawa, 2004, Int. J. Mol. Med., 13, 69
- Chaoui, 2006, Cytometry B Clin. Cytom., 70, 189, 10.1002/cyto.b.20100 · doi:10.1002/cyto.b.20100
- McDonald, 2000, Int. J. Oncol., 16, 871
- Takimoto, 2002, Cancer Biol. Ther., 1, 47, 10.4161/cbt.1.1.41 · DOI
- Wang, 2005, Cancer Biol. Ther., 4, 893, 10.4161/cbt.4.8.2134 · DOI
- Luo, 2001, Cancer Res., 61, 8158
- Mihara, 2003, Mol. Cell., 11, 577, 10.1016/S1097-2765(03)00050-9 · DOI · Paper page
Cited by
Cytoplasmic functions of the tumour suppressor p53
Green, D. R., & Kroemer, G. (2009) · Nature · doi:10.1038/nature07986 · Cited by 1,106
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
The mitochondrial pathways of apoptosis
Estaquier, J., Vallette, F., Vayssiere, J.-L., & Mignotte, B. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_7 · Cited by 637
“This chapter reviews our current knowledge on the mitochondrial pathway of apoptosis with a particular emphasis to new aspects of the regulation of the Bcl-2 proteins family control of mitochondrial membrane permeabilization (MOMP) and the mechanisms implicated in their mitochondrial targeting and activation, the func…”
InfluentialFrom keratinocyte to cancer: the pathogenesis and modeling of cutaneous squamous cell carcinoma
Ratushny, V., Gober, M. D., Hick, R., Ridky, T. W., & Seykora, J. T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57415 · Cited by 545
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Metadata
- Authors
- Tang, X., Zhu, Y., Han, L., Kim, A. L., Kopelovich, L., Bickers, D. R., & Athar, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-12-03
- Volume
- 117
- Issue
- 12
- Pages
- 3753-3764
- ISSN
- 0021-9738
- Cited by
- 124
- References
- 9
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.